Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD2 | Q9BYW2 | 14/20 | 0.48 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.47 |
| ▸ | NSD2 | O96028 | 3/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607409 | 1.00 | SETD2 (0.48) | SETD2SMYD3NSD2CYP2C8DRD2 | |
| SCHEMBL3607941 | 0.93 | SETD2 (0.52) | SETD2SMYD3NSD2CYP2C8DRD2 | |
| SCHEMBL3607939 | 0.93 | SETD2 (0.52) | SETD2SMYD3NSD2CYP2C8DRD2 | |
| SCHEMBL3608204 | 0.86 | SMYD3 (0.46) | SETD2SMYD3NSD2CYP2C8DRD2 | |
| SCHEMBL3602150 | 0.86 | SMYD3 (0.46) | SETD2SMYD3NSD2CYP2C8DRD2 | |
| SCHEMBL3602154 | 0.86 | SMYD3 (0.46) | SETD2SMYD3NSD2CYP2C8DRD2 | |
| SCHEMBL3595497 | 0.83 | SMYD3 (0.50) | SMYD3KDM1A | |
| SCHEMBL3611578 | 0.83 | SMYD3 (0.50) | SETD2SMYD3NSD2KDM1A | |
| SCHEMBL3606352 | 0.83 | SMYD3 (0.69) | SETD2SMYD3NSD2 | |
| SCHEMBL3595499 | 0.83 | SMYD3 (0.50) | SMYD3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | SETD2 2175/4885SMYD3 811/4885NSD2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.